The move follows the World Health Organisation's Emergency Use Listing for Covaxin, which is the second most used formulation in India.
The Centre on Wednesday placed a second purchase order with the Serum Institute of India for the supply of one crore doses of Oxford-AstraZeneca COVID-19 vaccine 'Covishield', each costing Rs 210, including GST, sources said.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries.
Briefing the media in Rome, Goyal said the Leaders adopted the 'Rome Declaration' at the G20 Summit and the communique gives a very strong message under the health section with the countries agreeing that the COVID-19 immunisation is a global public good.
Each vaccination session will cater to a maximum of 100 beneficiaries and the Union Health Ministry has advised states not to organise 'unreasonable numbers of vaccination per site per day'.
Hiring activity in the country touched an all-time high in July, witnessing a 11 per cent sequential increase, indicating a strong revival of economic growth and a recovery of business from the impact of COVID-19, a report said on Friday. With 2,625 job postings, hiring trends grew 11 per cent in July compared with 2,359 postings in June, the highest it has ever been, including the pre-COVID-19 timeline, according to the report by Naukri JobSpeak. The Indian job market has witnessed sequential growth for the second month in a row, with a 15 per cent rise in June, after the pandemic-linked decline in April and May, it stated.
865 million Indian adults require vaccination.
Companies are offering services in drug discovery and validation based on pathway analysis (that is, analysis of how toxic or radioactive substances reach humans), genomics (study of gene sequences in living organisms), proteomics (large-scale study of proteins) and translational research (clinical investigation with human patients or volunteers).
Delhi requires 80 lakh doses a month to vaccinate its youth. But it only received 16 lakh doses in May. The Centre has further decreased Delhi's quota in June to 8 lakh doses, Kejriwal said.
So far, no other vaccine has been approved globally for children below 12 years. Sohini Das reports.
The phase-three human clinical trial of indigenously developed anti-coronavirus vaccine candidate Covaxin began at the AIIMS in New Delhi on Thursday, with Dr M V Padma Srivastava, the chief of Neurosciences Centre at the premier institute, and three other volunteers receiving the first dose.
In the major Indian cities, the Omicron variant of the coronavirus is accounting for more than 50 per cent of the fresh cases of the infection and the massive surge in the number of cases over the last one week is indicative of a third wave of the pandemic, as is being witnessed in several countries, Dr N K Arora, chairman of the COVID-19 working group of the NTAGI, said on Tuesday.
'Please don't read something which is not there in DG, ICMR's letter. The intent of the letter is only to expedite duly approved clinical trials without compromising on security and safety concerns'
Cadila, Biocon developing rapid antibody testing kits; Eris, Mylan, Gland importing. There are two kinds of testing for the novel coronavirus - the real-time polymerase chain reaction test kit that uses throat or nasal swabs and provides results in a few hours, and the other is antibody-based rapid testing kit that use blood samples and provides results in a few minutes.
While the Indian government has been procuring Covid-19 vaccines at low prices so far, manufacturers have to declare the prices of vaccines they would supply to the open market (industries, private hospitals, etc) and state governments before May 1. Sohini Das reports.
'Just put a patch on your arm and the vaccine can be absorbed by the body.'
Chennai born Meera Mitun landed her first modelling break when she least expected it.
The IOA had also urged five Olympic-bound sportspersons, who have recovered from COVID-19 in the recent past, to take their first dose of the vaccine as soon as possible.
Prime Minister Narendra Modi took second dose of COVID-19 vaccine at the AIIMS in New Delhi, and asked those eligible for the shot to take it soon to defeat the virus.
There was speculation that a one-time special Covid-19 cess would be imposed and that it would raise an estimated Rs 18,000 crore.
Pfizer sought to participate in the Subject Expert Committee consultations towards an emergency use authorisation for its Covid-19 vaccine. However, the company representatives have been unable to participate in the meetings because of extremely short notices of a few hours or less and time-zone limitations.
The government plans to immunise 30 million people in the first phase, starting February, and by July, the target is to vaccinate 250 million people, reports Sohini Das.
"We will never approve anything if there is even the slightest safety concern. Vaccines are 110 per cent safe. Some side effects like mild fever, pain and allergy are common for every vaccine. "It (rumours of impotency) is complete nonsense," V G Somani, Drug Controller General of India said.
India is currently using two vaccines for COVID-19 -- one developed by Oxford University and AstraZeneca and the other developed by Bharat Biotech in collaboration with the Indian Council of Medical Research-National Institute of Virology. Both the vaccines are being manufactured within the country by domestic firms.
The decline in the effectiveness of Covaxin, India's indigenous COVID-19 vaccine, from 77.8 per cent to 50 per cent during a Delta-driven case surge in April and May this year is neither bad nor surprising, say scientists.
Dispatch of the vaccine is likely to start by early Tuesday morning, sources said. According to the order placed, each dose of the vaccine has been priced at Rs 200 and with GST of Rs 10, it would cost Rs 210.
The industry needs a 10 year extension of tax benefits for standalone R&D entities.
Once available, Sputnik V will be the third vaccine to be used in India against coronavirus.
The Indian government and private firms have stepped up efforts to develop a vaccine to halt the spread of COVID-19 which has claimed over 3,700 lives with more than 1,25,000 cases in the country.
India and the Netherlands on Tuesday signed a memorandum of understanding for cooperation in biotechnology with an aim to find solutions to problems in agricultural and health
Union Health Minister Mansukh Mandaviya on Tuesday told Bharatiya Janata Party MPs that Covid vaccination for children is likely to start soon, sources said.
During the meeting, scheduled to be held through video conference at 6 pm on Tuesday, the Department of Biotechnology will make a presentation and also coordinate with all the participants, sources added.
By 2022, there is a plan to make an mRNA-technology vaccine, for which it has tied up with Canadian firm Providence Therapeutics.
Asserting that India offers unprecedented opportunities for entrepreneurs in biotechnology industry, Minister of State for Science and Technology Kapil Sibal has invited venture capitalists, experts in the field and non-resident Indians to invest the
Mumbai Mayor Kishori Pednekar on Tuesday said if the daily Covid-19 cases in the city cross the 20,000-mark, a lockdown will be imposed in the city as per the Union government's rules.
The primary market is set for a bumper Rs 80,000-crore bonanza with 30 companies already filing IPO papers to raise Rs 55,000 crore, while around 10 more are lined up for this month itself, seeking to mop up another Rs 25,000 crore, say investment bankers. The market has been on a non-stop rally, hitting new records almost every week, on the back of an influx of investors -- a vast majority of them first-timers -- coupled with a flood of liquidity. Foreign funds alone had pumped in a record $35 billion into the market in FY21, while the trend has continued this fiscal as well. Domestic institutions led by LIC have also infused trillions of rupees, helping woo retail investors in troves -- the year saw over 20 million new investors coming to the market.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances